Myeloma bone disease and proteasome inhibition therapies.
about
A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphomaChanges in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter studyThe effects of proteasome inhibitors on bone remodeling in multiple myeloma.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsBone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genesProteasome inhibition and its therapeutic potential in multiple myelomaBortezomib in the management of multiple myeloma.Molecular imaging in myeloma precursor disease.Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.Bortezomib in the front-line treatment of multiple myeloma.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Cancer phenotype as the outcome of an evolutionary game between normal and malignant cellsDickkopf-1: a suitable target for the management of myeloma bone disease.Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.Soluble molecules and bone metabolism in multiple myeloma: a review.Proteasome inhibitors and bone disease.E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins.The ecology of cancer from an evolutionary game theory perspective.Myeloma Propagating Cells, Drug Resistance and Relapse.Current Controversies in the Management of Myeloma Bone Disease.E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models.Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaRelationship between abnormal osteoblasts and cellular immunity in multiple myeloma.Bone building with bortezomib.Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.Osteogenic inhibition in multiple myeloma.Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.Role of bortezomib for the treatment of previously untreated multiple myeloma.The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.Evaluation and management of skeletal disease in cancer care.
P2860
Q33705439-8B335754-2BB9-4E63-890C-49E070EFE745Q33891364-47D9329E-AE51-49EF-B029-DF76BA52870FQ33918020-5C17F046-E56E-4689-A4BF-F9AACBFD04BCQ34038854-8400FBAB-05AF-4776-9AAA-7676686D633BQ34155848-BC0666DB-C05F-4677-B1FF-5BD980683AA0Q34203659-E96ED5C6-4644-4966-BF82-9AA3C5B1401EQ34343036-18394EAD-A8A6-4D7C-A02B-3BBC71B651E9Q34418462-A4C697E8-97D1-4B02-BD0D-C02AAEEB8A66Q34505016-55ED3753-0230-4A10-B5D5-64D0F15DC1CBQ34997270-76503CCC-44DE-44D4-952B-8A6DE8483D5AQ35422468-636247AE-B15B-4712-B36D-3BC0606D0CD5Q36162703-09994BE4-8A5E-4522-A522-DBE1F65A16C6Q36234799-484FEAA2-37BB-4A29-9F89-459885E6EA54Q37166798-EBAF53B5-3B54-4B1C-87CE-1D9C5E827CB6Q37176560-57C7F589-68C1-4C53-84BA-96636157E1F0Q37202761-2E6E4F3D-C61A-4D12-BB32-C1BE4A826917Q37348247-E01A74F2-18A2-4516-B98E-FD360DE9F690Q37400506-C3441A85-C957-4F63-A107-44696571F7BAQ37521086-7F08AE6A-B0BC-4DF7-A66C-F1508DBE5482Q37668104-A3570E2A-2281-4E0D-AE82-494A3EC5F310Q37998401-42F388FA-39E3-4C4F-90E9-8FDAA432E2F4Q38021042-FEE98170-85B4-4386-BF7A-1CAFE3BE3861Q38074797-5A4539AA-E56C-4D64-A77B-9859087030D9Q38089906-E7B4B74B-C790-45A6-A742-F29AE504F0DBQ38237394-C06E8299-7F7D-405C-8986-9DF5BD7808C3Q38572771-60CFDE5B-E44E-40EB-A1F1-539C54C24312Q38748577-C3845CF2-6C8B-4F84-91F1-4F52F70F2530Q38814167-DA96D6F7-6AD8-4CA9-BAE8-19E618CD3054Q39377326-35FF4A74-ADBC-4849-9932-882DE450CEB3Q39768627-2F7C0F4F-4EAD-4FF1-B0F8-305E9C685095Q41194729-FA53D77E-B05B-42EE-8D72-80211B97CB34Q41844119-3AA36276-BBD0-4503-8D57-DEEA65547273Q41884185-4A0BC316-8173-4AAD-A109-072AD42F550EQ42597494-F9EDB0EE-E87F-4D01-B88D-53D127DE534CQ42710172-3549F05F-1EE2-4635-87C3-A447E0056C1FQ42807448-E1E2E2E9-2A65-4133-A145-BB067A55BDC3Q42932963-FB80C501-3268-4D33-A1F4-4A15D1D61C35Q45786963-E7BD077A-DCFD-466C-8C7C-4B0680BBF080Q46246952-DA7FE7DD-C652-4860-B5EA-7AB1A665E68AQ50070694-A3A6E71B-6B17-45D9-8AA3-239D1BE5A699
P2860
Myeloma bone disease and proteasome inhibition therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Myeloma bone disease and proteasome inhibition therapies.
@ast
Myeloma bone disease and proteasome inhibition therapies.
@en
type
label
Myeloma bone disease and proteasome inhibition therapies.
@ast
Myeloma bone disease and proteasome inhibition therapies.
@en
prefLabel
Myeloma bone disease and proteasome inhibition therapies.
@ast
Myeloma bone disease and proteasome inhibition therapies.
@en
P1433
P1476
Myeloma bone disease and proteasome inhibition therapies
@en
P2093
Evangelos Terpos
Orhan Sezer
P304
P356
10.1182/BLOOD-2007-03-067710
P407
P577
2007-05-09T00:00:00Z